EASD 2026: The combination of semaglutide/cagrilintide altered food-cue responses and showed a 22.4% estimated weight difference vs placebo; separate data found less organ fat in type 2 diabetes.
|Articles|October 27, 2020
What do you Know about Weight Loss Medications?
Author(s)Alex Evans, PharmD, MBA
Weight loss is essential to arrest the cardiovascular disease and metabolic dysfunction linked to obesity. What do you know about the drugs now available that may help?
Advertisement
With overweight and obesity reaching
Advertisement
Related to this article
Endocrine Society statement highlights key research gaps on obesity drugs—who benefits, long-term dosing, safety, and measuring success beyond weight loss.
A new scientific statement calls for a shift in obesity management and treatment to focus on overall health improvements rather than just weight loss alone.
Semaglutide brought 40.4% of children below the obesity BMI threshold, according to top-line results from the phase 3 STEP Young clinical trial.
US clinicians increasingly prescribe GLP-1 drugs to young children with obesity, although overall use remains limited and access disparities persist.
September FDA news included updates in CKD and type 1 diabetes, major depressive disorder, insulin pump technology, alopecia areata, and more.
EADV 2026: Lebrikizumab improved hand and foot clearance, itch, and pain at 16 weeks versus placebo in a phase 3b atopic dermatitis trial.
The FDA accepted Bayer's sNDA and granted Priority Review to elinzanetant for vasomotor symptoms in women on endocrine therapy for HR+ breast cancer.
Advertisement
Advertisement
Trending on Patient Care Online
1
Lebrikizumab Improves Hand and Foot Atopic Dermatitis in Phase 3b Trial
2
CagriSema Alters Food-Cue Responses, Reduces Organ Fat in New Analyses
3
Detecting Atrial Fibrillation in Primary Care: Warning Signs and Modifiable Risk Factors
4
Beyond Semaglutide and Tirzepatide: The Next Wave of Obesity Medicines
5